Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 12/20 | 0.53 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.49 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.49 |
| ▸ | PTGDR | Q13258 | 5/20 | 0.47 |
| ▸ | PTGER2 | P43116 | 4/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.47 |
| ▸ | PDE5A | O76074 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | HTR5A | P47898 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15126357 | 0.87 | PTGDR2 (0.60) | PTGDR2PTGDRPTGER2CYP2C9HTR5A | |
| SCHEMBL600037 | 0.82 | AKR1B10 (0.70) | PTGDR2AKR1B10AKR1B1PDE5AKDM4E | |
| SCHEMBL600939 | 0.78 | PTGDR2 (0.65) | PTGDR2AKR1B10AKR1B1PTGDRPTGER2 | |
| SCHEMBL3094301 | 0.77 | PTGDR2 (0.76) | PTGDR2PTGDRPTGER2CYP2C9KDM4E | |
| SCHEMBL3081745 | 0.76 | PTGDR2 (0.70) | PTGDR2AKR1B10AKR1B1PTGDRPTGER2 | |
| SCHEMBL15126360 | 0.75 | AKR1B10 (0.52) | PTGDR2AKR1B10AKR1B1PTGDRPTGER2 | |
| SCHEMBL601773 | 0.74 | AKR1B10 (0.64) | PTGDR2AKR1B10AKR1B1PDE5A | |
| SCHEMBL3085042 | 0.72 | PTGDR2 (0.70) | PTGDR2PTGDRPTGER2CYP2C9 | |
| SCHEMBL23148492 | 0.72 | PTGDR2 (0.59) | PTGDR2AKR1B10AKR1B1PTGDRPTGER2 | |
| SCHEMBL23148497 | 0.72 | MAPT (0.48) | CYP2C9KDM4EALDH1A1MAPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170096426-A1 | Novel Tricyclic Modulators of Cannabinoid Receptors | THE UNIV OF MONTANA (US) | 2017-04-06 | — | — | US | claimed |
| US-20120039804-A1 | Novel Tricyclic Modulators of Cannabinoid Receptors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-02-16 | — | — | US | claimed |
| US-20170096426-A1 | Novel Tricyclic Modulators of Cannabinoid Receptors | THE UNIV OF MONTANA (US) | 2017-04-06 | — | — | US | disclosed |
| US-20170096426-A1 | Novel Tricyclic Modulators of Cannabinoid Receptors | THE UNIV OF MONTANA (US) | 2017-04-06 | — | — | US | disclosed |
| US-20170096426-A1 | Novel Tricyclic Modulators of Cannabinoid Receptors | THE UNIV OF MONTANA (US) | 2017-04-06 | — | — | US | disclosed |
| WO-2013106460-A2 | COMPOSITIONS AND METHODS FOR TREATING MALIGNANT ASTROCYTOMAS | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2013-07-18 | — | — | WO | disclosed |
| US-20120039804-A1 | Novel Tricyclic Modulators of Cannabinoid Receptors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-02-16 | — | — | US | disclosed |
| US-20120039804-A1 | Novel Tricyclic Modulators of Cannabinoid Receptors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-02-16 | — | — | US | disclosed |
| US-20120039804-A1 | Novel Tricyclic Modulators of Cannabinoid Receptors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120039804-A1 | Novel Tricyclic Modulators of Cannabinoid Receptors | CNR1, CNR2, OPRL1 | PTGDR2 110/4885AKR1B10 1854/4885AKR1B1 2366/4885 |
| US-20170096426-A1 | Novel Tricyclic Modulators of Cannabinoid Receptors | CNR1, CNR2, OPRL1 | PTGDR2 110/4885AKR1B10 1854/4885AKR1B1 2366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.